Menu
Search
|

Menu

Close
X

Akari Therapeutics PLC AKTX.OQ (NASDAQ Stock Exchange Capital Market)

1.66 USD
-0.09 (-5.14%)
As of 9:16 PM IST
chart
Previous Close 1.75
Open 1.74
Volume 319
3m Avg Volume 10,916
Today’s High 1.74
Today’s Low 1.66
52 Week High 5.49
52 Week Low 1.63
Shares Outstanding (mil) 0.12
Market Capitalization (mil) 71.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.006
FY17
-0.028
FY16
-0.015
FY15
-0.089
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
3.11
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-68.01
15.05
Return on Equity (TTM)
vs sector
-68.13
16.62

EXECUTIVE LEADERSHIP

Ray Prudo
Chairman of the Board, Since 2017
Salary: --
Bonus: --
David Solomon
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Dov Elefant
Chief Financial Officer, Since 2012
Salary: $200,000.00
Bonus: --
Clive Richardson
Chief Operating Officer, Director, Since 2015
Salary: --
Bonus: --
Nigel Hernandez
Vice President - Worldwide Regulatory Affairs, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

75/76 Wimpole Street
LONDON   NY   W1G 9RS

Phone: +4420.80040261
Site: akaritx.com/

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

SPONSORED STORIES